Insider Trading April 13, 2026 06:19 PM

NeonC Technologies C.A.O. David Suh Jr. Buys $1,000 of Stock as Company Advances Financing and Clinical Program

Small insider purchase accompanies $16 million private placement, legal settlement and preparations to disclose Phase 1/2 trial data

By Nina Shah NTHI
NeonC Technologies C.A.O. David Suh Jr. Buys $1,000 of Stock as Company Advances Financing and Clinical Program
NTHI

NeonC Technologies Holdings, Inc. (NASDAQ:NTHI) reported an insider purchase by Chief Accounting Officer David Suh, Jr., who acquired 200 shares at $5.00 per share on April 9, 2026. The company has also disclosed prior equity grants to Suh, a $16 million private placement, resolution of a legal dispute with Fox Infused, LLC, a leadership appointment, and plans to present initial data from its NEO212-01 Phase 1/2 clinical trial.

Key Points

  • NeonC Technologies Holdings, Inc. (NASDAQ:NTHI) reported a Form 4 showing Chief Accounting Officer David Suh, Jr. bought 200 shares at $5.00 per share on April 9, 2026, totaling $1,000.
  • On March 1, 2026, Suh was granted 111,666 shares of restricted common stock and 58,334 performance-based restricted common stock.
  • NeOnc Technologies Holdings Inc. completed a $16 million private placement selling common stock and warrants, settled a legal dispute with Fox Infused, LLC for $737,920.77, appointed David Choi as Chief Accounting Officer, and is preparing to present initial NEO212-01 Phase 1/2 clinical trial data including safety, toxicity, and pharmacokinetics.

NeonC Technologies Holdings, Inc. (NASDAQ:NTHI) disclosed a recent insider transaction in a Form 4 filed with the Securities and Exchange Commission: Chief Accounting Officer David Suh, Jr. purchased 200 shares of the company’s common stock at $5.00 per share on April 9, 2026, for a total reported value of $1,000.

The same filing notes an earlier equity award to Suh on March 1, 2026, consisting of 111,666 shares of restricted common stock and 58,334 shares of performance-based restricted common stock.


Alongside the insider activity, NeOnc Technologies Holdings Inc. announced a $16 million capital raise executed through a private placement. The transaction involved the sale of common stock and warrants and was presented by the company as a source of additional resources for ongoing operations.

The company also reported the settlement of a legal matter with Fox Infused, LLC, resulting in a payment of $737,920.77. This resolution was disclosed as part of the company’s recent corporate and financial updates.


In a separate leadership note, NeOnc Technologies said that David Choi has been appointed as the Chief Accounting Officer, with responsibility for the company’s accounting and financial reporting functions.

On the development front, the company is preparing to present initial data from its NEO212-01 Phase 1/2 clinical trial. The forthcoming presentation will include findings related to safety, toxicity, and pharmacokinetics. The company indicated the report will cover dose-escalation observations and planned regulatory steps tied to the clinical program.


These items were disclosed in recent filings and company announcements and collectively describe a mix of insider activity, equity compensation, corporate financing, legal resolution, leadership changes, and near-term clinical data milestones for NeonC Technologies.

Readers should note that the Form 4 filing documents the specific insider purchase and the March equity grants; the private placement, settlement amount, leadership appointment, and clinical trial presentation were outlined separately by the company.

Risks

  • The company faces ongoing clinical and regulatory uncertainty tied to the NEO212-01 Phase 1/2 trial; outcomes on safety, toxicity, and pharmacokinetics remain to be presented and could affect development plans.
  • Financial and operational plans are dependent in part on the recently completed $16 million private placement; future funding needs and dilution could arise if additional capital is required.
  • Legal and governance developments, including the settlement with Fox Infused, LLC and the reported accounting leadership changes, introduce execution and oversight risks that may affect financial reporting and corporate operations.

More from Insider Trading

Micron EVP Disposes $1.43 Million in Shares as Analysts Split on Outlook Apr 13, 2026 Zoom CFO Sells $690,330 in Stock as Company Reports Solid Q4 and Expands AI Offerings Apr 13, 2026 Photronics Director Disposes $220,000 in Stock as Options Are Exercised Apr 13, 2026 ChargePoint CEO Richard Wilmer Buys $249,999 in Company Stock as Firm Reports Mixed Q4 Results Apr 13, 2026 Alignment Healthcare CEO Disposes of $6.16 Million in Stock Amid Recent Share Strength Apr 13, 2026